Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06527690 | Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer(REPRESENTATION) | withdrawn | Phase 2 | 0 | Latin American Cooperative Oncology GroupOTHER | 0 | Sep 29, 2025 | clinicaltrials |
| NCT03974204 | Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis. | withdrawn | N/A | 0 | Centre Oscar LambretOTHER | 1 |
| Sep 26, 2025 |
| clinicaltrials |
| NCT04344652 | Photoscreening for Retinoblastoma | withdrawn | N/A | 0 | Phoenix Children's HospitalOTHER | 0 | Sep 26, 2025 | clinicaltrials |
| NCT06597773 | Online Patient Navigation Program for Patients With Breast Cancer | withdrawn | N/A | 0 | Medicos e Investigadores en la Lucha contra el Cancer de MamaOTHER | 1 | Sep 26, 2025 | clinicaltrials |
| NCT01326468 | Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer | withdrawn | N/A | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | Sep 25, 2025 | clinicaltrials |
| NCT06528210 | Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Sep 23, 2025 | clinicaltrials |
| NCT02869282 | Circulating And Intra-Tumoral Chemokines In Patients With Prostate Cancer(CHEMOPROST) | withdrawn | — | 0 | Institut BergoniéOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT04372641 | Testing the Safety of CB-5339 in Patients With Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2025 | clinicaltrials |
| NCT04784221 | Nanoparticles and Hypofractionated Protontherapy for Reirradiation of Pantumor Relapse(NANOPRO) | withdrawn | Phase 2 | 0 | Centre Francois BaclesseOTHER | 0 | Sep 17, 2025 | clinicaltrials |
| NCT06058728 | A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)(Pink Orchid) | withdrawn | — | 0 | AbbVieINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06670105 | A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06672224 | Indocyanine Green Fluoroscopy and SPY Angiography for the Assessment of Lymphatic Structure in Breast Cancer Patients at Risk for Breast Cancer-Related Lymphedema | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 0 | Sep 17, 2025 | clinicaltrials |
| NCT05472623 | Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab(Neo-Kan) | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06746324 | Assessing AI for Detecting Lung Nodules and Cancer: Pre- and Post-Deployment Study(AI-Lung) | withdrawn | — | 0 | University of FloridaOTHER | 0 | Sep 15, 2025 | clinicaltrials |
| NCT00466830 | Psychological and Social Factors and Risk Chronic Pain After Surgery in Women With Breast Cancer(SDPM) | withdrawn | — | — | Institut BergoniéOTHER | 0 | Sep 11, 2025 | clinicaltrials |
| NCT06410534 | A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2025 | clinicaltrials |
| NCT06690281 | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2025 | clinicaltrials |
| NCT00210171 | Concomitant Chemo-radiotherapy in Locally Advanced Non Small Cell Lung Cancer(BIB 01) | withdrawn | Phase 2 | 0 | Institut BergoniéOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT06276946 | Sparing Parotid Ducts Via MRI Sialography for Reduced Patient Reported Xerostomia | withdrawn | N/A | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT00210145 | Socio-aesthetic Intervention on Body Image and Quality of Life in Women With Breast Cancer.(ASE K SEIN) | withdrawn | — | 0 | Institut BergoniéOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT04557709 | Major Complication Rate in Cancer Patients With Neutropenic Fever Potentially Eligible for a Hospital at Home Program | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 4, 2025 | clinicaltrials |
| NCT06084689 | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures(EMPIRE) | withdrawn | Phase 2 | 0 | Institut BergoniéOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT04053114 | MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii(MOLTHYSO) | withdrawn | — | 0 | Institut BergoniéOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT04580667 | Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict GI Radiation Toxicity | withdrawn | — | 0 | DiaCarta, Inc.INDUSTRY | 1 | Aug 28, 2025 | clinicaltrials |
| NCT06217016 | Effect of ICCAUT Strategy on Postoperative Urinary Retention After Radical Rectal Cancer Surgery (ICCAUT-2) | withdrawn | N/A | 0 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT06420908 | Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) | withdrawn | N/A | 0 | Hebei Medical University Fourth HospitalOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT06670976 | Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT06555263 | Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Sutro Biopharma, Inc.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT06361810 | PSMA Therapy and Immunotherapy in Kidney Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT04756765 | Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer | withdrawn | Phase 2 | 0 | Stanford UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06762808 | Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 15, 2025 | clinicaltrials |
| NCT05052632 | Evaluating a New Gonadotoxic Risk Stratification System | withdrawn | — | 0 | University of Colorado, DenverOTHER | 0 | Aug 13, 2025 | clinicaltrials |
| NCT07011849 | Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 13, 2025 | clinicaltrials |
| NCT04118036 | Abemaciclib + Pembrolizumab In Glioblastoma | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06005649 | Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Juventas Cell Therapy Ltd.INDUSTRY | 0 | Aug 8, 2025 | clinicaltrials |
| NCT06009107 | A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)(B-ALL) | withdrawn | Phase 1 / Phase 2 | 0 | Juventas Cell Therapy Ltd.INDUSTRY | 0 | Aug 8, 2025 | clinicaltrials |
| NCT06676917 | Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain Metastases(TUXEDO-5) | withdrawn | Phase 2 | 0 | MedSIROTHER | 0 | Aug 8, 2025 | clinicaltrials |
| NCT05717140 | Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT05000905 | Improving Cognition and Behavior in Pediatric Cancer Survivors Using a Novel Mindful Attention Training | withdrawn | N/A | 0 | University of California, San FranciscoOTHER | 0 | Aug 6, 2025 | clinicaltrials |
| NCT06474663 | A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 6, 2025 | clinicaltrials |
| NCT07038915 | STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1 | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 5, 2025 | clinicaltrials |
| NCT06362421 | Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer | withdrawn | — | 0 | Wake Forest University Health SciencesOTHER | 0 | Jul 31, 2025 | clinicaltrials |
| NCT05678205 | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Artiva Biotherapeutics, Inc.INDUSTRY | 2 | Jul 30, 2025 | clinicaltrials |
| NCT04615884 | Use of Chinese Herbal Formula Shu Yu Wan in Lung Cancer Patients(CH:II) | withdrawn | N/A | 0 | Lady Davis InstituteOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT05917990 | Dyadic Text-Messaging Micro-Intervention | withdrawn | N/A | 0 | Duke UniversityOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT05634525 | Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT04571710 | A Trial of SHR1258 in Patients With Biliary Tract Cancer | withdrawn | Phase 2 | 0 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Jul 24, 2025 | clinicaltrials |
| NCT06501911 | A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma | withdrawn | Phase 1 | 0 | University of NebraskaOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT06235541 | A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | Genome & CompanyINDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06246786 | Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer) | withdrawn | Early Phase 1 | 0 | Virginia G. KaklamaniOTHER | 1 | Jul 16, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 29, 2025source: clinicaltrials